Safety Study of Repeat Doses of SUSTOL in Adults
brief summary
This was a repeat-dose, single-arm, open-label study that evaluated the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy \[MEC\] or Anthracycline and Cyclophosphamide \[AC\] combination regimen).
detailed description
This study was a post-marketing requirement (PMR) study with a planned sample size of 300 subjects. The Sponsor stopped the study upon release from the PMR, with 24 subjects having participated.
official title
A Phase 4, Open-Label Safety Study of Repeat Doses of SUSTOL in Adult Subjects Receiving Chemotherapy